# Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT07381582** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 161Tb-LNC1011

## Key facts

- **NCT ID:** NCT07381582
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381582, "Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07381582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*